Want to see AU:NTI full AI Analyst Report?
NTI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume11.09K
Average Volume (3M)768.84K
Market Cap
AU$23.72M
Enterprise ValueAU$9.84M
Total Cash (Recent Filing)AU$6.34M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,317,741,700
10 Day Avg. Volume770,041
30 Day Avg. Volume768,844
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.26
Price to Sales (P/S)6.36
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$3.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt materially lowers solvency and refinancing risk for a cash-burning biotech. This structural conservatism preserves strategic optionality, giving management time to pursue trials, partnerships or targeted raises without immediate debt servicing pressure over the next several months.
High Gross Margin ProfileA reported 100% gross margin implies product or revenue streams with negligible direct costs, indicating scalable unit economics if commercialized. Sustained high gross margins would allow incremental revenue to flow to the operating line faster, improving leverage as sales scale over 2-6 months and beyond.
Focused Neurological Therapy PipelineA clear strategic focus on neurological disorders aligns with persistent, structural unmet medical needs and potential for long-term grant, partnership and licensing opportunities. Specialization can attract collaborators and targeted funding, supporting sustained R&D progress across multiple reporting periods.
Bears Say
Accelerating Cash BurnWorsening free cash flow signals growing funding needs and heightens dilution or financing risk. For a development-stage biotech, sustained negative FCF constrains ability to fund trials or commercialization without external capital, increasing execution risk over the coming 2-6 months.
Shrinking Equity BaseA rapidly reduced equity cushion limits the company's ability to absorb further losses and may force more frequent or dilutive raises. Reduced shareholder equity also weakens balance-sheet credibility with partners and lenders, raising funding vulnerability in the medium term.
Persistent Operating LossesOperating costs materially exceed current scale, producing sustained negative margins. Without meaningful revenue scale or cost reductions, profitability remains remote, constraining free cash flow improvement and heightening dependence on external capital over multiple quarters.
Neurotech International News
NTI FAQ
What was Neurotech International Ltd.’s price range in the past 12 months?
Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Neurotech International Ltd.’s market cap?
Neurotech International Ltd.’s market cap is AU$23.72M.
When is Neurotech International Ltd.’s upcoming earnings report date?
Neurotech International Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 42 days.
How were Neurotech International Ltd.’s earnings last quarter?
Neurotech International Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.
Is Neurotech International Ltd. overvalued?
According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued.
Does Neurotech International Ltd. pay dividends?
Neurotech International Ltd. does not currently pay dividends.
What is Neurotech International Ltd.’s EPS estimate?
Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurotech International Ltd. have?
Neurotech International Ltd. has 1,317,741,700 shares outstanding.
What happened to Neurotech International Ltd.’s price movement after its last earnings report?
Neurotech International Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Neurotech International Ltd.?
Currently, no hedge funds are holding shares in AU:NTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurotech International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.87%
Trailing 12-Months
Company Description
Neurotech International Ltd.
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder. Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―